
Opinion|Videos|May 12, 2025
Factors Contributing to Higher Incidence and Worse Outcomes of mHSPC in Black Men
Author(s)Quoc-Dien Trinh, MD, MPH
A panelist discusses how the differences in prostate cancer among Black men are multifactorial, including biological differences in risk alleles, social determinants of health, and limited access to care and clinical trials.
Advertisement
Episodes in this series

Multifactorial Causes of Racial Disparities
Key Themes:
- Disparities have complex, multifactorial origins.
- Biological differences include potentially different risk alleles in African American men.
- Social determinants of health significantly impact outcomes.
- Access to care, including clinical trials, remains problematic for Black men.
Key Points for Physicians:
- Consider biological and social factors when managing Black patients.
- Address potential socioeconomic barriers to treatment adherence.
- Facilitate clinical trial access when appropriate treatment options exist.
Notable Insights: The combination of biological differences and socioeconomic factors creates a complex landscape requiring multifaceted interventions at individual and systemic levels.
Clinical Significance: Understanding the interplay between biological and social factors is essential for developing effective strategies to reduce prostate cancer disparities in Black men.
Advertisement
Related to this article

Mark D. Tyson, II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.

An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.

This FAQ outlines key recommendations and practical takeaways from the AUA/SUO guideline amendment on the diagnosis and treatment of NMIBC.

Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.

The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.

Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
Avoiding False Positives on Prostate Cancer PSMA PET Scans
2
2026 AUA/SUO NMIBC guideline: Key updates for clinical practice
3
Decipher may help identify ADT benefit in intermediate-risk prostate cancer
4
AUA South Central Section Meeting: Mark D. Tyson, II, MD, MPH, recaps data in NMIBC
5


